Insight Molecular Diagnostics Inc.
IMDX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2 | $2 | $1 | $2 |
| % Growth | 25.1% | 56.9% | -56.4% | – |
| Cost of Goods Sold | $1 | $1 | $1 | $1 |
| Gross Profit | $1 | $0 | -$0 | $1 |
| % Margin | 39.3% | 27.5% | -1.9% | 64.6% |
| R&D Expenses | $10 | $9 | $7 | $5 |
| G&A Expenses | $13 | $13 | $22 | $20 |
| SG&A Expenses | $14 | $13 | $22 | $20 |
| Sales & Mktg Exp. | $1 | $0 | $0 | $0 |
| Other Operating Expenses | $38 | $3 | -$11 | $30 |
| Operating Expenses | $62 | $26 | $18 | $55 |
| Operating Income | -$61 | -$25 | -$18 | -$54 |
| % Margin | -3,245.1% | -1,672.4% | -1,878.6% | -2,444.3% |
| Other Income/Exp. Net | $0 | $0 | -$1 | $1 |
| Pre-Tax Income | -$61 | -$25 | -$19 | -$53 |
| Tax Expense | $0 | $0 | $0 | -$9 |
| Net Income | -$61 | -$28 | -$73 | -$64 |
| % Margin | -3,225% | -1,848.4% | -7,609.8% | -2,916.2% |
| EPS | -4.661 | -3.75 | -20 | -14.4 |
| % Growth | -24.3% | 81.3% | -38.9% | – |
| EPS Diluted | -4.661 | -3.75 | -20 | -14.4 |
| Weighted Avg Shares Out | 13 | 8 | 6 | 4 |
| Weighted Avg Shares Out Dil | 13 | 8 | 6 | 4 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $2 | $5 | $4 |
| EBITDA | -$59 | -$23 | -$13 | -$48 |
| % Margin | -3,137.4% | -1,538.5% | -1,389.2% | -2,204.6% |